chlorambucil has been researched along with Lymphoma, B-Cell, Marginal Zone in 35 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with histologically verified MALT lymphoma undergoing chemotherapy with MCP were evaluated retrospectively." | 5.32 | Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). ( Chott, A; Dirisamer, A; Drach, J; Hejna, M; Püspök, A; Raderer, M; Scheithauer, W; Wöhrer, S, 2003) |
| "The aetiological association between MALT lymphomas and Helicobacter pylori is well established." | 2.74 | Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. ( Ambrosetti, A; Burton, C; Capella, C; Cavalli, F; Copie-Bergman, C; Cortelazzo, S; Delchier, JC; Ferreri, AJ; Gisselbrecht, C; Hancock, BW; Jakupovic, I; Levy, M; Linch, D; Martinelli, G; Pinotti, G; Qian, W; Smith, P; Souhami, R; Traulle, C; Vitolo, U; Wotherspoon, A; Zucca, E, 2009) |
| "Less than half of the patients with MALT lymphoma can achieve sustained molecular remission after anti-Helicobacter therapy." | 2.70 | Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. ( Bertoni, F; Biondi, A; Capella, C; Cavalli, F; Cazzaniga, G; Conconi, A; Cotter, FE; Giardini, R; Hancock, BW; Motta, T; Novero, D; Pedrinis, E; Ponzoni, M; Rinaldi, P; Smith, P; Souhami, R; Wotherspoon, A; Zucca, E, 2002) |
| "The diagnosis of MALT lymphoma with adenoma on a background of Crohn's disease was made." | 2.61 | Synchronous colonic adenoma and intestinal marginal zone B-cell lymphoma associated with Crohn's disease: a case report and literature review. ( Achraf, M; Bennani, A; Imane, K; Kharrasse, G; Mohamed, B; Wafa, K; Zahi, I, 2019) |
| "Disease progression was significantly more frequent in patients presenting an immunological event or an M component." | 2.41 | Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. ( Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C, 2002) |
| "We present a case of oral mucosal MALT lymphoma with clinical features simulating oral-facial granulomatosis." | 1.34 | Oral mucosal MALT lymphoma clinically simulating oral facial granulomatosis. ( Gerami, P, 2007) |
| "Pathology revealed orbital MALT lymphoma with B-cell monoclonality." | 1.33 | Detection of Chlamydia pneumoniae in a bilateral orbital mucosa-associated lymphoid tissue lymphoma. ( Chan, CC; Chan, NR; Galita, DA; Shen, D; Yuen, HK, 2006) |
| "Patients with histologically verified MALT lymphoma undergoing chemotherapy with MCP were evaluated retrospectively." | 1.32 | Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). ( Chott, A; Dirisamer, A; Drach, J; Hejna, M; Püspök, A; Raderer, M; Scheithauer, W; Wöhrer, S, 2003) |
| "In conclusion, MALT lymphoma of the lung should be considered in the differential diagnosis of progressive lung disease in CVID." | 1.31 | Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome. ( Cathomas, G; Gonon, M; Reichenberger, F; Tamm, M; Wyser, C, 2001) |
| "Localized MALT lymphomas have excellent prognosis following moderate-dose RT." | 1.31 | Stage I and II MALT lymphoma: results of treatment with radiotherapy. ( Bezjak, A; Crump, M; Gospodarowicz, MK; Hodgson, DC; Pintilie, M; Tsang, RW; Wells, W, 2001) |
| "Low-grade B-cell MALT lymphoma was diagnosed by histologic and immunohistologic examination of endoscopic biopsies." | 1.29 | Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. ( Chaumette, MT; Delchier, JC; Divine, M; Gaulard, P; Haioun, C; Hammel, P; Reyes, F, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.43) | 18.2507 |
| 2000's | 18 (51.43) | 29.6817 |
| 2010's | 12 (34.29) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Lévy, M | 5 |
| Dupuis, J | 2 |
| Charpy, C | 1 |
| Martin, A | 1 |
| Itti, E | 1 |
| Sobhani, I | 3 |
| Haioun, C | 4 |
| Amiot, A | 2 |
| Bennani, A | 1 |
| Kharrasse, G | 1 |
| Achraf, M | 1 |
| Wafa, K | 1 |
| Zahi, I | 1 |
| Imane, K | 1 |
| Mohamed, B | 1 |
| Schauer, C | 1 |
| Cunliffe, R | 1 |
| Ruiz-Medrano, J | 1 |
| Peralta-Díaz, LM | 1 |
| Santos-Bueso, E | 1 |
| Raimundo, S | 1 |
| Alexandre, A | 1 |
| Pinto, C | 1 |
| Hancock, BW | 2 |
| Qian, W | 1 |
| Linch, D | 1 |
| Delchier, JC | 5 |
| Smith, P | 2 |
| Jakupovic, I | 1 |
| Burton, C | 1 |
| Souhami, R | 2 |
| Wotherspoon, A | 3 |
| Copie-Bergman, C | 5 |
| Capella, C | 3 |
| Traulle, C | 2 |
| Cortelazzo, S | 1 |
| Ferreri, AJ | 1 |
| Ambrosetti, A | 1 |
| Pinotti, G | 2 |
| Martinelli, G | 2 |
| Vitolo, U | 2 |
| Cavalli, F | 4 |
| Gisselbrecht, C | 1 |
| Zucca, E | 4 |
| Kalpadakis, C | 1 |
| Pangalis, GA | 1 |
| Vassilakopoulos, TP | 1 |
| Kyrtsonis, MC | 1 |
| Siakantaris, MP | 1 |
| Kontopidou, FN | 1 |
| Korkolopoulou, P | 1 |
| Bobotsis, P | 1 |
| Sahanas, S | 1 |
| Tzenou, T | 1 |
| Anagnostou, D | 1 |
| Dimitriadou, E | 1 |
| Yiakoumis, X | 1 |
| Patsouris, E | 1 |
| Roussou, P | 1 |
| Panayiotidis, P | 1 |
| Papadaki, E | 1 |
| Angelopoulou, MK | 1 |
| Borie, R | 1 |
| Wislez, M | 1 |
| Thabut, G | 1 |
| Antoine, M | 1 |
| Rabbat, A | 1 |
| Couderc, LJ | 1 |
| Monnet, I | 1 |
| Nunes, H | 1 |
| Blanc, FX | 1 |
| Mal, H | 1 |
| Bergeron, A | 1 |
| Dusser, D | 1 |
| Israël-Biet, D | 1 |
| Crestani, B | 1 |
| Cadranel, J | 1 |
| Molinier-Frenkel, V | 1 |
| Riou, A | 1 |
| Gaulard, P | 3 |
| Delfau-Larue, MH | 2 |
| Leroy, K | 2 |
| Mirabile, A | 1 |
| Devizzi, L | 1 |
| Gianni, AM | 1 |
| Cabras, A | 1 |
| Carbone, A | 1 |
| Velázquez, D | 1 |
| de Pablo, P | 1 |
| García, D | 1 |
| Ramírez, JR | 1 |
| Breton, AL | 1 |
| Poulalhon, N | 1 |
| Balme, B | 1 |
| Thomas, L | 1 |
| Dalle, S | 1 |
| Marco, S | 1 |
| Thariat, J | 1 |
| Poudenx, M | 1 |
| Butori, C | 1 |
| Mouroux, J | 1 |
| Fuzibet, JG | 1 |
| Marquette, CH | 1 |
| Peyrade, F | 1 |
| Thyss, A | 1 |
| Le Baleur, Y | 1 |
| Belhadj, K | 1 |
| Hémery, F | 2 |
| Leblond, V | 2 |
| Johnson, S | 1 |
| Chevret, S | 1 |
| Copplestone, A | 1 |
| Rule, S | 1 |
| Tournilhac, O | 1 |
| Seymour, JF | 1 |
| Patmore, RD | 1 |
| Wright, D | 1 |
| Morel, P | 1 |
| Dilhuydy, MS | 1 |
| Willoughby, S | 1 |
| Dartigeas, C | 1 |
| Malphettes, M | 1 |
| Royer, B | 1 |
| Ewings, M | 1 |
| Pratt, G | 1 |
| Lejeune, J | 1 |
| Nguyen-Khac, F | 1 |
| Choquet, S | 1 |
| Owen, RG | 1 |
| Conconi, A | 2 |
| Laszlo, D | 1 |
| López-Guillermo, A | 1 |
| Bouabdallah, R | 1 |
| Coiffier, B | 2 |
| Sebban, C | 1 |
| Jardin, F | 1 |
| Morschhauser, F | 1 |
| Pileri, SA | 1 |
| Campo, E | 1 |
| Jack, A | 1 |
| Floriani, I | 1 |
| Johnson, P | 1 |
| Martelli, M | 1 |
| Thieblemont, C | 2 |
| Felman, P | 1 |
| Berger, F | 1 |
| Dumontet, C | 1 |
| Arnaud, P | 1 |
| Hequet, O | 1 |
| Arcache, J | 1 |
| Callet-Bauchu, E | 1 |
| Salles, G | 1 |
| Novik, AA | 1 |
| Denisov, NL | 1 |
| Gershanovich, ML | 1 |
| Pozharisskiĭ, KM | 1 |
| Gorodokin, I | 1 |
| Wöhrer, S | 1 |
| Drach, J | 1 |
| Hejna, M | 1 |
| Scheithauer, W | 1 |
| Dirisamer, A | 1 |
| Püspök, A | 1 |
| Chott, A | 1 |
| Raderer, M | 1 |
| Hon, C | 1 |
| Au, WY | 1 |
| Chung, LP | 1 |
| Choy, C | 1 |
| Manoharan, A | 1 |
| Michael, CW | 1 |
| Richardson, PH | 1 |
| Boudreaux, CW | 1 |
| Ben Simon, GJ | 1 |
| Cheung, N | 1 |
| McKelvie, P | 1 |
| Fox, R | 1 |
| McNab, AA | 1 |
| Shen, D | 1 |
| Yuen, HK | 1 |
| Galita, DA | 1 |
| Chan, NR | 1 |
| Chan, CC | 1 |
| Arkenau, HT | 1 |
| Gordon, C | 1 |
| Cunningham, D | 1 |
| Norman, A | 1 |
| Chau, I | 1 |
| Rigacci, L | 1 |
| Nassi, L | 1 |
| Puccioni, M | 1 |
| Mappa, S | 1 |
| Polito, E | 1 |
| Dal Pozzo, S | 1 |
| Alterini, R | 1 |
| Carrai, V | 1 |
| Puccini, B | 1 |
| Bosi, A | 1 |
| Gerami, P | 1 |
| Hammel, P | 1 |
| Chaumette, MT | 1 |
| Divine, M | 1 |
| Reyes, F | 1 |
| Roggero, E | 1 |
| Pascarella, A | 1 |
| Bertoni, F | 2 |
| Savio, A | 1 |
| Savio, E | 1 |
| Pedrinis, E | 2 |
| Saletti, P | 1 |
| Morandi, E | 1 |
| Santandrea, G | 1 |
| Bornand-Rousselot, A | 1 |
| Saint-Jean, O | 1 |
| Mak, SK | 1 |
| Wong, PN | 1 |
| Lo, KY | 1 |
| Wong, AK | 1 |
| Reichenberger, F | 1 |
| Wyser, C | 1 |
| Gonon, M | 1 |
| Cathomas, G | 1 |
| Tamm, M | 1 |
| Tsang, RW | 1 |
| Gospodarowicz, MK | 1 |
| Pintilie, M | 1 |
| Bezjak, A | 1 |
| Wells, W | 1 |
| Hodgson, DC | 1 |
| Crump, M | 1 |
| Lavergne-Slove, A | 1 |
| Brousse, N | 1 |
| Flejou, JF | 1 |
| de Mascarel, A | 1 |
| Motta, T | 1 |
| Giardini, R | 1 |
| Ponzoni, M | 1 |
| Novero, D | 1 |
| Rinaldi, P | 1 |
| Cazzaniga, G | 1 |
| Biondi, A | 1 |
| Cotter, FE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma[NCT00003617] | Phase 3 | 200 participants (Anticipated) | Interventional | 1995-03-31 | Active, not recruiting | ||
| Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma[NCT00566332] | Phase 3 | 414 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes[NCT00608374] | Phase 3 | 400 participants (Anticipated) | Interventional | 2006-06-30 | Completed | ||
| Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)[NCT00210353] | Phase 3 | 454 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Response criteria were defined according to the NCI standardized response criteria for non-Hodgkin's lymphoma.~Complete response. Disappearance of all detectable clinical and radiographic evidence of disease, disappearance of all disease-related symptoms, if present before therapy, and normalization of those biochemical abnormalities definitely assignable to NHL. Regression of all lymph nodes and nodal masses to normal (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy and to ≤ 1 cm for nodes that were 1.1-1.5 cm. Regression by more than 75% in the sum of the products of the greatest diameters).~Partial response. Decrease by at least 50% in SPD of the six largest measurable lesions. It is not necessary for all lesions to have regressed to qualify for partial response, but no lesion should have progressed and no new lesion should appear.~For primary gastric sites, response was based on GELA histologic grading system." (NCT00210353)
Timeframe: End of treatment (after 24 weeks of therapy)
| Intervention | percentage of patients (Number) |
|---|---|
| ARM A - Chlorambucil | 85.5 |
| ARM B - Rituximab + Chlorambucil | 94.7 |
| ARM C (Since April 2006) - Rituximab | 78.3 |
Percentage of patients without events (failure of treatment or Death from any cause) after 5 years from trial registration (NCT00210353)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| ARM A - Chlorambucil | 51 |
| ARM B - Rituximab + Chlorambucil | 68 |
| ARM C (Since April 2006) - Rituximab | 51 |
Percentage of patients alive after 5 years from trial registration (NCT00210353)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| ARM A | 89 |
| ARM B | 90 |
| ARM C (Since April 2006) | 92 |
Percentage of patients without disease progression after 5 years from trial registration (NCT00210353)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| ARM A - Chlorambucil | 59 |
| ARM B - Rituximab + Chlorambucil | 72 |
| ARM C (Since April 2006) - Ritiximab | 57 |
"Response criteria were defined according to the NCI standardized response criteria for non-Hodgkin's lymphoma.~Complete response (CR). Disappearance of all detectable clinical and radiographic evidence of disease, disappearance of all disease-related symptoms, if present before therapy, and normalization of those biochemical abnormalities definitely assignable to NHL. Regression of all lymph nodes and nodal masses to normal (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy and to ≤ 1 cm for nodes that were 1.1-1.5 cm. Regression by more than 75% in the sum of the products of the greatest diameters)." (NCT00210353)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| ARM A - Chlorambucil | 70 |
| ARM B - Rituximab + Chlorambucil | 79 |
| ARM C (Since April 2006) - Rituximab | 66 |
5 reviews available for chlorambucil and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Synchronous colonic adenoma and intestinal marginal zone B-cell lymphoma associated with Crohn's disease: a case report and literature review.
Topics: Adenoma; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Biopsy; Chlorambuc | 2019 |
Primary cutaneous marginal zone lymphoma as a complication of radiation therapy: Case report and review.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2010 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin | 2002 |
[Helicobacter pylori infection and gastric MALT lymphoma: present-day approaches to research and treatment].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chr | 2002 |
Successful treatment of IgA nephropathy in association with low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Chlorambucil; Combined Modality Therapy; Gastric Mucosa; | 1998 |
9 trials available for chlorambucil and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Disease-Free Survival; | 2009 |
Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2010 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estim | 2013 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estim | 2013 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estim | 2013 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estim | 2013 |
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2013 |
Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambuci | 2006 |
Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineopla | 1997 |
Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.
Topics: Adult; Aged; Amoxicillin; Antineoplastic Agents, Alkylating; Biopsy, Needle; Chlorambucil; Clarithro | 2002 |
Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Disease-Free Survival; False Negative Reactions; Fo | 2002 |
21 other studies available for chlorambucil and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Case-Control | 2022 |
Marginal Zone Lymphoma of the Entire Gastrointestinal Tract.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Colonic Neoplasms; Duodenal Neop | 2018 |
Orbitary MALT lymphoma in a patient diagnosed with non-Hodgkin lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; H | 2015 |
Tracheal Secondary Involvement by mucosa-associated lymphoid tissue Lymphoma - A Rare Diagnosis.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bronchoscopy; | 2016 |
Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Female; Humans; Lymphoma, B-Cel | 2008 |
Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambucil; Cyclophosphamide; D | 2009 |
MALT lymphoma and Kaposi sarcoma in an HIV-negative patient.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2010 |
Primary cutaneous marginal zone B-cell lymphoma: An atypical case.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineopl | 2010 |
[Six cases of pulmonary MALT lymphoma: a heterogeneous therapeutic management].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2011 |
Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dis | 2003 |
Long-standing Bell's palsy and ipsilateral conjunctival maltoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bell Palsy; Chlorambucil; Conjunctival Diseases; Female; F | 2004 |
Sustained remissions with long-term weekly chlorambucil maintenance therapy in patients with mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; | 2004 |
Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclo | 2005 |
Detection of Chlamydia pneumoniae in a bilateral orbital mucosa-associated lymphoid tissue lymphoma.
Topics: Antineoplastic Agents, Alkylating; Chlamydophila Infections; Chlamydophila pneumoniae; Chlorambucil; | 2006 |
Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Oral mucosal MALT lymphoma clinically simulating oral facial granulomatosis.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Diagnosis, Differential; Female; Granulomatosis, Or | 2007 |
Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chlorambuci | 1995 |
Sequential chlorambucil and prednisone as second line therapy in gastric malt lymphoma resistant to Helicobacter pylori eradication. A case report in an octogenarian patient.
Topics: Aged; Aged, 80 and over; Chlorambucil; Drug Therapy, Combination; Female; Helicobacter Infections; H | 1998 |
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.
Topics: Adult; Biopsy, Needle; Chlorambucil; Common Variable Immunodeficiency; Diagnosis, Differential; Drug | 2001 |
Stage I and II MALT lymphoma: results of treatment with radiotherapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Co | 2001 |